- Report
- April 2025
- 290 Pages
Global
From €5331EUR$5,850USD£4,554GBP
- Report
- April 2025
- 175 Pages
Global
From €4092EUR$4,490USD£3,495GBP
- Report
- April 2025
- 200 Pages
Global
From €4092EUR$4,490USD£3,495GBP
- Report
- May 2024
- 139 Pages
Global
From €5923EUR$6,499USD£5,059GBP
- Report
- May 2024
- 130 Pages
Global
From €5923EUR$6,499USD£5,059GBP
- Report
- October 2024
- 318 Pages
Global
From €7245EUR$7,950USD£6,188GBP
- Report
- May 2024
- 200 Pages
Global
From €3782EUR$4,150USD£3,230GBP
- Report
- March 2024
- 30 Pages
Global
From €2962EUR$3,250USD£2,530GBP
- Report
- February 2024
- 115 Pages
Global
From €4329EUR$4,750USD£3,697GBP
- Report
- February 2024
- 112 Pages
Global
From €3500EUR$4,114USD£3,094GBP
- Report
- April 2025
- 50 Pages
Global
From €2415EUR$2,650USD£2,063GBP
- Report
- November 2021
- 844 Pages
Global
From €4557EUR$5,000USD£3,892GBP

Pramipexole is a dopamine agonist used to treat symptoms of Parkinson's disease, restless leg syndrome, and other conditions. It is a member of the class of drugs known as central nervous system (CNS) drugs, which are used to treat neurological disorders. Pramipexole works by activating dopamine receptors in the brain, which helps to reduce the symptoms of Parkinson's disease and other conditions. It is available in both immediate-release and extended-release formulations.
Pramipexole is a widely used CNS drug, with a large market share in the United States and Europe. It is available in both generic and branded forms, and is prescribed by doctors for the treatment of Parkinson's disease and other neurological disorders.
Several companies are involved in the Pramipexole market, including Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Other companies involved in the market include Actavis, Sandoz, and Dr. Reddy's Laboratories. Show Less Read more